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Abstract 
Background: The pathogenesis of chronic obstructive pulmonary disease (COPD) is associated 
with dyslipidemia, an established co-morbidity. Statins treat hypercholesterolemia, but more 
recently have been trailed in the setting of COPD for their potential anti-inflammatory benefits. 
The outcomes of prospective trials however have been inconsistent. Thus, we hypothesize that 
the variation in results may have been due to statin-induced downregulation of ATP-binding 
cassette transporter A1 (ABCA1), thereby reducing cholesterol export. This study aims to 
elucidate whether statin treatment in a cellular model of COPD leads to a decrease in ABCA1 
protein expression.  
Methods: To mimic the inflammatory environment of COPD, two commonly used lung 
epithelial cell lines (BEAS-2B and A549) were treated with tumor necrosis factor (TNF), and co-
treated with cholesterol/25-hydroxycholesterol (25-OH) to mimic dyslipidemia. ABCA1 protein 
was detected by Western Blotting. 
Results: We unexpectedly showed that statins did not affect ABCA1 expression. However, the 
LXR agonist T0901317 significantly increased ABCA1 expression in both cell lines, while TNF, 
cholesterol or 25-OH induced ABCA1 protein upregulation in BEAS-2B cells, indicating cell 
line differences in response. There was also evidence of synergistic impacts of combined 
treatments on ABCA1 upregulation in BEAS-2B cells.  
Conclusion: statins did not have an impact on ABCA1 expression in lung epithelial cell lines, 
disproving our original hypothesis. However, we showed for the first time, the effect of the 
inflammatory cytokine TNF, cholesterol/25-OH, statins and the LXR agonist T0901317 on 
expression of ABCA1 transporter protein in human lung epithelial cell lines in vitro. We hope 
 3 
that these in vitro studies may prove beneficial for addressing dyslipidemia in COPD in the 
future.  
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Introduction 
The current therapies for chronic obstructive pulmonary disease (COPD) address symptomatic 
control to improve quality of life for people living with COPD. Yet, declining lung function 
continues somewhat unabated due to the fact that inflammation in COPD is relatively refractory 
to corticosteroids. In recent years, dyslipidemia has been recognised as a co-morbidity of COPD 
and a contributor to disease pathogenesis in COPD [1]. Elevated levels of cholesterol [2, 3], or 
oxidized derivatives, such as the oxysterol 25-hydroxycholesterol [4], have been linked to 
inflammation and other pathologies in COPD. Statins are the conventional treatment for 
hypercholesterolemia and have also been the subject of extensive research to exploit the potential 
pleiotropic beneficial effects in COPD, reduction of inflammation in particular, beyond their 
lipid-lowering impact (reviewed in [5, 6]). Cumulative in vitro evidence and multiple 
retrospective clinical studies provided a therapeutic rationale behind the Prospective Randomized 
Placebo-Controlled Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) 
[7]. However, the outcomes from STATCOPE were discordant with earlier observational studies 
that demonstrated significant reduction in exacerbations (reviewed in [8]).  
Although there are a number of reasons for the failure of statins to live up to their promise in 
STATCOPE, including patient selection and aspects of study design [8] or oral delivery route 
[5], in this study we propose an alternative hypothesis. We propose that the disparity may be due 
to statin-induced downregulation of one of the major transporter proteins responsible for 
removing intracellular cholesterol (a process known as cholesterol efflux) namely the ABCA1 
(ATP-binding cassette A1) transporter. Statins are known to reduce ABCA1 in the 
cardiovascular context [9-11], but whether statins have a similar repressive impact on ABCA1 in 
COPD is unknown at present. The importance of ABCA1, and the critical role it plays in 
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cholesterol efflux and homeostasis, has emerged recently in chronic respiratory disease 
(reviewed in [12]). Knocking-out ABCA1 in mice results in excessive pulmonary inflammation 
and abnormalities [13], while conversely, mice overexpressing ABCA1 have attenuated 
neutrophilic airway inflammation [14]. More recently, cigarette smoke, a major risk factor in 
COPD, has been shown in in vivo and in vitro studies [15-17] to significantly decrease ABCA1 
expression resulting in impaired cholesterol efflux, exaggerated inflammatory phenotype and 
hallmark features of COPD. Moreover, studies are now emerging that explore the therapeutic 
potential of agonists directed towards Liver X Receptors (LXR) [18] to upregulate ABCA1 in an 
attempt to counter cigarette smoke-induced impact in the context of COPD [19].  
Taken together, these studies place ABCA1 as a critical regulator of lipid homeostasis and 
underscore the importance of research that links dyslipidemia and inflammation in COPD. We 
model this herein, by utilizing commonly-used lung epithelial cell lines (BEAS-2B and A549) 
treated with tumor necrosis factor (TNF) to simulate the inflammatory environment in COPD, 
and cholesterol and 25-hydroxycholesterol to model dyslipidemia. In this study, we use our in 
vitro model to examine the hypothesis that: 1) statins will decrease ABCA1 expression in lung 
epithelial cells; and 2) that synthetic LXR agonist T0901317 will reverse the statin-induced 
ABCA1 decrease.  
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Materials and Methods 
Chemicals 
TNF was purchased from R&D Systems (Minneapolis, MN). Atorvastatin calcium salt 
trihydrate, simvastatin (lactone), cholesterol, methyl-betacyclodextrin and T0901317 were from 
Sigma Aldrich (St. Louis, MO). Unless otherwise specified, all other chemicals used in this study 
were purchased from Sigma Aldrich (St. Louis, MO). 25-hydroxycholesterol (25-OH) was 
purchased from Avanti Polar Lipids. Cholesterol and 25-OH were complexed to cyclodextrin as 
described in Yang and Gelissen [20]. 
 
 
Epithelial cell culture 
The immortalized bronchial epithelial cell line BEAS-2B and the adenocarcinoma epithelial cell 
line A549 were purchased from the American Type Culture Collection (ATCC) and cultured in 
feeding media composed of Dulbecco’s Modified Eagle’s medium-low glucose, supplemented 
with streptomycin (10,000 μg/mL), penicillin (10,000 units/mL), L-glutamine (200 mM) and 
heat-inactivated foetal bovine serum (10%), under conditions of 37˚C incubation in a 5% CO2 
atmosphere.  
 
Cell treatments, cell lysis and protein equilibration 
Cells were seeded into 12-well plates at density of 105 cell/ml. After 48 h, treatments were added 
according to experimental conditions for a further 24 h. After treatment, 12-well plates were 
placed on ice, in preparation for cell lysis. The cells were washed twice with cold PBS, before 
being lysed with cell lysis buffer composed of IGEPAL buffer (1% IGEPAL detergent, 50 mM 
Tris, 150 mM NaCl, pH 7.8) and protease inhibitor cocktail (5 μg/mL). Cells were collected by 
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scraping, lysates collected and cellular DNA sheared by repeated drawing up and down through 
a 23-gauge syringe. The cell lysate was then centrifuged at 14,000 r.p.m at 4˚C for 5 minutes and 
total protein concentration of cell lysates was measured using the Bicinchoninic Acid (BCA) 
Assay kit (Sigma Aldrich) and the proteins equilibrated prior to SDS-PAGE and Western 
blotting.  
 
SDS-PAGE and Western blotting  
ABCA1 was detected by Western blotting after 6% SDS-PAGE gels and anti-ABCA1 antibody 
((1/2500, mouse monoclonal IgG1, clone AB.H10: Merck, Darmstadt, Germany). HSP-70 was 
used as a loading control (1/5000, mouse monoclonal IgG1, clone BRM-22: Sigma-Aldrich). 
Primary antibodies were detected with goat anti-mouse HRP-conjugated secondary antibodies 
(1/2000, Cell Signaling Technology, Danvers, MA) and visualized by enhanced 
chemiluminescence (PerkinElmer, Wellesley, MA). Western blots depicted in the figures are 
representative results all run on the same gel. 
 
Statistical analysis 
Statistical analysis was performed using the one-way ANOVA then Bonferroni’s multiple 
comparison test.  p values < 0.05 were sufficient to reject the null hypothesis for all analyses.  
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Results 
Effect of TNF or cholesterol/25-OH, alone and in combination, on ABCA1 protein 
expression in BEAS-2B and A549 cells: establishing the in vitro model of COPD and 
dyslipidemia  
In our in vitro model, the two lung epithelial cell lines (BEAS-2B and A549) are treated with 
TNF to model inflammatory conditions occurring in COPD, while cholesterol or 25-OH 
stimulation mimicked the condition of dyslipidemia. The results shown in Figure 1 serve to 
establish our in vitro model of COPD and dyslipidemia. Firstly, we show that the low level of 
basal ABCA1 protein expression in BEAS-2B cells can be significantly upregulated with TNF 
(2.5±0.1-fold), cholesterol (4.4±0.3-fold), or 25-OH (5.2±0.3-fold), compared to untreated 
control cells (Figure 1A: p<0.05). Secondly, to model the impact of dyslipidemia on the inflamed 
epithelium, BEAS-2B cells were stimulated with cholesterol/25-OH in the presence of TNF. As 
shown in Figure 1A, the simultaneous treatment of BEAS-2B with TNF + cholesterol or TNF + 
25-OH increased ABCA1 protein expression by 6.3±0.5-fold or 8.2±0.9-fold, respectively, 
compared to untreated cells (p<0.05). The effect of combined treatments on ABCA1 protein 
upregulation in BEAS-2B was additive. In contrast, the pattern of ABCA1 upregulation in A549 
cells (Figure 1B) differed from BEAS-2B (Figure 1A): that is, A549 cells expressed no 
significant changes in ABCA1 expression from basal levels when stimulated with TNF, 
cholesterol and 25-OH. However, there was a synergistic upregulation when A549 cells were 
stimulated with cholesterol or 25-OH in the presence of TNF; the combined stimuli resulted in 
significant increases in the ABCA1 expression (TNF + cholesterol 8.2±0.6-fold: TNF + 25-OH 
8.6±0.8-fold) (Figure 1B: p<0.05).  
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Effect of the LXR agonist T0901317, and the statins simvastatin and atorvastatin, on 
ABCA1 expression in BEAS-2B and A549 cells 
We then treated BEAS-2B and A549 cells with increasing concentrations (0.5 – 10 µM) of the 
synthetic LXR agonist T0901317 and examined the effect on ABCA1 protein levels (Figure 2). 
As shown in Figure 2A, T0901317 significantly induced ABCA1 production at all 
concentrations tested (p<0.05). A similar pattern of ABCA1 protein upregulation was observed 
after treatment of A549 cells with T0901317 (Figure 2B: p<0.05).  
While it was expected that LXR agonists would increase ABCA1 expression (1 µM was chosen 
for future experiments), it was unknown whether statins modulate basal levels of ABCA1 
protein. To address this, we conducted a pilot study whereby BEAS-2B and A549 were treated 
with increasing concentrations (0.5 – 10 µM) of two statins, simvastatin and atorvastatin, for 24 
h before ABCA1 protein levels were measured by Western blotting. Negative controls were 
untreated cells, while positive controls were cells treated with TNF. In confirmation of earlier 
results, TNF induced ABCA1 protein upregulation in BEAS-2B (Figures 3A and 3B), but not 
A549 cells (Figures 3C and 3D). Notably, neither simvastatin nor atorvastatin resulted in a 
visible effect on basal ABCA1 expression in both BEAS-2B (Figures 3A and 3B) and A549 
(Figures 3C and 3D) cell lines; thus, future experimentation will utilise 10 µM. 
 
Statins have no effect on ABCA1 protein expression in an in vitro model of COPD and 
dyslipidemia 
Our experiments thus far have established the in vitro model of COPD and dyslipidemia; BEAS-
2B are the preferred epithelial cell line given significant ABCA1 upregulation under both 
inflamed (TNF) and/or dyslipidaemic conditions (cholesterol/25-OH). We also have determined 
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the relevant concentrations of LXR agonist and statins to use to address our study hypothesis that 
statins will decrease ABCA1 expression in lung epithelial cells and T0901317 will ameliorate 
this decrease. 
Counter to our hypothesis however, simvastatin (10 µM) did not induce a significant decrease in 
ABCA1 protein level under any conditions in our in vitro COPD and dyslipidemia model (Figure 
4). Specifically, as shown in Figure 4A, TNF stimulation significantly increased ABCA1 protein 
upregulation by 2.2±0.2-fold (p<0.05), but simvastatin did not repress TNF-induced ABCA1 
protein levels. Cholesterol and 25-OH stimulation (Figures 4B and 4C) also significantly 
increased ABCA1 protein (3.2±0.4-fold and 4.1±0.3-fold, respectively: p<0.05), but again, 
simvastatin was without effect. Finally, there was no impact of simvastatin on ABCA1 protein 
produced by simultaneous treatment of BEAS-2B cells with TNF + cholesterol (Figure 4D) or 
TNF + 25-OH (Figure 4E). Taken together, these data show that simvastatin treatment does not 
decrease ABCA1 protein expression in BEAS-2B cells when stimulated with stimuli treated 
individually or in combination. The same experiments were performed with atorvastatin (10 µM) 
and, as shown in Figure 5, atorvastatin had no effect on ABCA1 protein expression in an in vitro 
model of COPD and dyslipidemia. 
 
Combined effect of T0901317, statins, and TNF, alone and in combination, on ABCA1 
protein expression in BEAS-2B cells 
Since we have disproved the first part of our study hypothesis by showing that statins do not 
decrease ABCA1 expression, whether synthetic LXR agonist T0901317 will reverse the statin-
induced ABCA1 decrease is now a moot point. However, given the interest in LXR agonists as 
potential therapeutics in chronic lung disease, we conducted a final experiment to examine the 
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effect of the LXR agonist T0901317, the statins simvastatin (Figure 6A) and atorvastatin (Figure 
6B), and the inflammatory cytokine TNF, alone and in combination, on ABCA1 protein 
upregulation in BEAS-2B cells. We were interested in whether additive or synergistic 
upregulation of ABCA1 protein expression would be achieved with treatments added in 
combination. As demonstrated in Figure 6A, and confirmation of earlier experiments, while 
T0901317 and TNF an increase in ABCA1 protein levels, simvastatin was without effect. When 
treatments were combined, the effect on ABCA1 upregulation was greater than additive, i.e. 
TNF (2.4±0.1-fold) T0901317 + simvastatin (5.6±0.3-fold); TNF + T0901317 + simvastatin 
(12.6±0.3-fold) (Figure 6A: p<0.05). The same pattern was observed in Figure 6B. These data 
show that treatments that induce ABCA1 expression individually (i.e. LXR agonists and TNF, 
but not statins) can co-contribute to enhance ABCA1 upregulation in a synergistic manner in 
BEAS-2B cells. 
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Discussion 
In this study, we examined ABCA1 protein upregulation in BEAS-2B and A549, two human cell 
lines commonly used to perform in vitro investigation of lung epithelial responses in chronic 
respiratory disease. We have shown that ABCA1 protein can be significantly upregulated in 
BEAS-2B cells after treatment with inflammatory cytokine TNF, cholesterol, and its oxidized 
derivative, 25-cholesterol, and the LXR agonist T0901317. Apart from TNF, these treatments 
also induced ABCA1 upregulation in A549 cells. There was evidence of additive and synergistic 
effects of these treatments in both cell types. The statins, simvastatin and atorvastatin, had no 
effect on ABCA1, alone or in combination with other treatments. 
Although the rationale for the current study was to model COPD and dyslipidemia in vitro and 
test the hypothesis that statins repress ABCA1 (and alternative hypothesis for the failure of 
STATCOPE), a hypothesis that was disproved by our experiments, our study has yielded new 
findings. Firstly, it shows for the first time that TNF upregulates ABCA1 protein in BEAS-2B, 
but not A549 cells. The impact of TNF on ABCA1 has previously been shown to be cell type 
specific [21] and may be related to TNF receptor expression [22]. Secondly, it demonstrates the 
utility of BEAS-2B cell lines for future studies of novel modulators and mechanisms of ABCA1 
expression. A549 cells have already been used to study ABCA1 in the past [23-25]. Although of 
course, use of primary epithelial cells are optimal, and this is a limitation of our study, we have 
confirmed the usefulness of epithelial cell lines as validatory tool. The need for these tools was 
recently exemplified in a seminal report by Aguiar et al. [17] that performed bioinformatic 
analysis of the gene expression pattern for the family of ABC transporters (48 in total) in airway 
epithelial cells from people with COPD or asthma. A lung epithelial cell line (Calu-3) was used 
to further interrogate ABC gene expression, the impact of cigarette smoke, and provide an 
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enabling platform to discover the underlying molecular mechanism of ABC transporter 
expression.  
Validated in vitro models are imperative because the need to understand regulation of ABC 
transporters, especially ABCA1, has come to the forefront recently through a renewed 
recognition of the importance of lipid homeostasis in respiratory disease and its co-morbidities. 
Airway cells, especially alveolar macrophages and type II pneumocytes, process considerable 
amounts of lipids to maintain a healthy equilibrium [12]. Thus, ABC lipid transporters have a 
critical protective role in the lung. However, this homeostasis can be perturbed with significant 
impact on disease pathogenesis. This was recently demonstrated by Sonett et al. [16] whereby 
cigarette smoke was shown to adversely affects cholesterol transport via an ABCA1-dependent 
mechanism in macrophages. Notably, downregulation of ABC transporters, particularly ABCA1, 
was observed in the lungs of patients diagnosed with COPD [16].  
ABCA1 expression therefore represents a putative, and modifiable, link between co-morbidities, 
given that atherosclerosis is more common in smokers with airway limitation, than in those with 
normal lung function [26]. Thus, it follows that upregulating ABCA1 has the potential to block 
cigarette smoke-induced impact on the lung. The LXR agonist T0901317 is a potent inducer of 
ABC transporters [27]; accordingly, Sonett et al. [16] performed in vitro experiments in 
macrophages, and in vivo murine models that mimic hallmark features of COPD, to show that 
LXR activation significantly alters lung function and structure after chronic cigarette smoke 
exposure in a manner linked to increased ABCA1 activity.  
Hence, pharmacological strategies that enhance ABCA1 activity may offer a novel therapeutic 
approach to reverse the damaging effects of cigarette smoke and protection from the 
development of COPD. In our study, we have shown that LXR agonist T0901317 robustly 
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increases ABCA1 protein upregulation in lung epithelial cell lines. However, further 
development and investigation of safe and specific LXR agonists are urgently required. This was 
underscored by the recent review of LXR agonists as potential therapeutics in inflammatory 
diseases [18] and the significant challenges encountered, including significant liver toxicity [18]. 
These challenges may be overcome through the development of LXRβ-selective agonists (there 
are two isoforms of LXR (LXRα and LXRβ) and LXRα activation has been associated with liver 
toxicity [18]) or tissue-selective agonism. It is important to note that T0901317 has affinity for 
both LXRα and LXRβ and newer, selective LXRβ agonists could be assessed in our in vitro 
model in lung epithelial cell lines. Finally, a recent in vivo study [19] pharmacological activation 
of LXR with T0901317 in mice exposed to cigarette smoke resulted in adverse effects related to 
perturbed pulmonary surfactant homeostasis. Given that surfactants are regulated by ABC 
transporters, selective pharmacological targeting of ABCA1 may have merit. 
A limitation of the current study is that the influence of statins, LXR agonist and other treatments 
on ABCA1 expression in lung epithelial cell lines was limited only to one type of analysis 
(Western blotting). Further investigations are warranted and could include investigation of 
transcriptional and post-transcriptional regulation of ABCA1 mRNA expression as well as 
delineation of the cellular signaling pathways responsible.  
In summary, our study disproved our original hypothesis, but overall provided useful data to 
show the effect of statins and the synthetic LXR agonist T0901317 on expression of ABCA1 
transporter protein in human lung epithelial cell lines in vitro.  
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Figure Legends 
Figure 1. Effect of TNF or cholesterol/25-OH, alone and in combination, on ABCA1 protein 
expression in BEAS-2B and A549 cells: establishing the in vitro model. (A) BEAS-2B and 
(B) A549 cells were left untreated or treated with TNF (10 ng/mL), cholesterol (5 μg/mL), 25-
OH (5 μg/mL), TNF + cholesterol, or TNF + 25-OH, for 24 h. Western blotting for ABCA1 was 
performed (compared to HSP-70 as loading control). Results are representative Western blots or 
densitometric analysis (normalized to HSP-70 and expressed as ABCA1 protein upregulation 
(fold change compared to untreated control cells)). Statistical analysis was performed using one-
way ANOVA then Bonferroni’s multiple comparison test (where * denotes a significant increase 
compared to untreated cells (p<0.05)). Data are mean+SEM values from n=3 independent 
experiments. 
 
Figure 2. Effect of the LXR agonist T0901317 on ABCA1 expression in BEAS-2B and A549 
cells. (A) BEAS-2B and (B) A549 cell lines were left untreated or treated with increasing 
concentrations of LXR agonist T0901317 (0.5 – 10 µM) for 24 h. Western blotting for ABCA1 
was performed (compared to HSP-70 as loading control). Results are representative Western 
blots or densitometric analysis (normalized to HSP-70 and expressed as ABCA1 protein 
upregulation (fold change compared to untreated control cells)). Statistical analysis was 
performed using one-way ANOVA then Bonferroni’s multiple comparison test (where * denotes 
a significant increase compared to untreated cells (p<0.05)). Data are mean+SEM values from 
n=3 independent experiments. 
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Figure 3. Effect of simvastatin or atorvastatin on ABCA1 expression in BEAS-2B and A549 
cells. (A, B) BEAS-2B and (C, D) A549 cell lines were either: left untreated, treated with TNF 
(10 ng/mL), or treated with decreasing concentrations (10 – 0.5 µM) of (A, C) simvastatin or (B, 
D) atorvastatin for 24 h. Western blotting for ABCA1 was performed (compared to HSP-70 as 
loading control). Results are Western blots from a pilot study (n=1). 
 
Figure 4. Simvastatin had no effect on ABCA1 protein expression in an in vitro model of 
COPD and dyslipidemia. BEAS-2B cells were treated with vehicle or simvastatin (10 µM) and 
then ABCA1 protein expression stimulated with (A) TNF (10 ng/mL), (B) cholesterol (5 
μg/mL), (C) 25-OH (5 μg/mL), (D) TNF + cholesterol, or (E) TNF + 25-OH, for 24 h, compared 
to untreated control cells. Western blotting for ABCA1 was performed (compared to HSP-70 as 
loading control). Results are representative Western blots or densitometric analysis (normalized 
to HSP-70 and expressed as ABCA1 protein upregulation (fold change compared to untreated 
control cells)). Statistical analysis was performed using one-way ANOVA then Bonferroni’s 
multiple comparison test (where * denotes a significant increase compared to untreated cells 
(p<0.05)). Data are mean+SEM values from n=3 independent experiments. 
 
Figure 5. Atorvastatin had no effect on ABCA1 protein expression in an in vitro model of 
COPD and dyslipidemia. BEAS-2B cells were treated with vehicle or atorvastatin (10 µM) and 
then ABCA1 protein expression stimulated with (A) TNF (10 ng/mL), (B) cholesterol (5 
μg/mL), (C) 25-OH (5 μg/mL), (D) TNF + cholesterol, or (E) TNF + 25-OH, for 24 h, compared 
to untreated control cells. Western blotting for ABCA1 was performed (compared to HSP-70 as 
loading control). Results are representative Western blots or densitometric analysis (normalized 
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to HSP-70 and expressed as ABCA1 protein upregulation (fold change compared to untreated 
control cells)). Statistical analysis was performed using one-way ANOVA then Bonferroni’s 
multiple comparison test (where * denotes a significant increase compared to untreated cells 
(p<0.05)). Data are mean+SEM values from n=3 independent experiments.  
 
Figure 6. Combined effect of T0901317, statins, and TNF, alone and in combination, on 
ABCA1 protein expression in BEAS-2B cells. BEAS-2B cells were treated with: (A) 
T0901317 (10 µM), simvastatin (10 µM), TNF (10 ng/mL), T0901317 + simvastatin, TNF + 
T0901317 + simvastatin; or (B) T0901317 (10 µM), atorvastatin (10 µM), TNF (10 ng/mL), 
T0901317 + simvastatin, TNF + T0901317 + atorvastatin, for 24 h, compared to untreated 
control cells. Western blotting for ABCA1 was performed (compared to HSP-70 as loading 
control). Results are representative Western blots or densitometric analysis (normalized to HSP-
70 and expressed as ABCA1 protein upregulation (fold change compared to untreated control 
cells)). Statistical analysis was performed using one-way ANOVA then Bonferroni’s multiple 
comparison test (where * denotes a significant increase (p<0.05)). Data are mean+SEM values 
from n=3 independent experiments. 
 
